News & Updates

In an effort to offer industry professionals more continuing education course options, PRN® Pharmacal partnered with Clinician’s Brief to leverage their existing comprehensive training platform. Effective January 1, 2022, all UniversityPRN.com courses were transferred...

The US Food and Drug Administration has granted KBroVet®-CA1 (potassium bromide chewable tablets) conditional approval for veterinary use in the management of seizures in dogs with idiopathic epilepsy. PRN® Pharmacal developed KBroVet-CA1 to provide a consistent and...